Amblyopia is an ocular disorder, commonly known as "Lazy Eye", whereby the individual receives the majority of the visual input from the dominant eye while the brain suppresses the visual input from the amblyopic eye. It is a developmental condition due to disrupted vision in one eye in infancy or early childhood. Accordingly, there is reduced vision in one eye and poor 3-D or depth vision. This disorder affects 3% of the world population or over 9 million people in the United States. Current treatment options are antiquated, ineffective and non-compliant. Research has shown that individuals who have amblyopia are likely to suffer from reading and learning disabilities.
Amblyotech has developed Binocuclear, a novel and patented therapy for the treatment of amblyopia through a series of video games. Binocuclear presents separate images (using red-blue glasses) with different components of the game to each eye, to encourage inter-ocular cooperation between the two eyes. Using a proprietary algorithm Binocuclear adjusts the contrast of the images seen by the fellow (good) eye while the amblyopic eye contrast is set at 100%. The amblyopic eye views at 100% contrast while the non-amblyopic eye is gradually incremented each day using an automatic algorithm based on daily successful game play. Binocuclear is imbedded in a dedicated electronic tablet device which will be available through physicians’ offices upon regulatory approval.
APDC is providing funding for Binocuclear's regulatory system and the development of a quality system.